Skip to content

Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain

Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain (WESTCOR Study)

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02620202
Acronym
WESTCOR
Enrollment
1900
Registered
2015-12-02
Start date
2015-09-30
Completion date
2020-05-31
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Troponin, Myocardial infarction

Brief summary

The main aim of the WESTCOR study is to * investigate the ability of two high sensitive cardiac troponin (hs-cTn) assays to diagnose acute coronary syndrome and predict prognosis in different patient populations (e.g. gender, age and co-morbidity) * to validate the suggested 1 hour protocol for rule in and rule out of acute coronary syndrome for two hs-cTn assays in an unselected chest pain population * to investigate different biomarkers ability to predict long term prognosis after hospitalization for chest pain

Detailed description

The WESTCOR-study will include patients presenting to the Emergency Department of Haukeland University Hospital and Stavanger University Hospital with symptoms indicative of acute coronary syndrome. 1500 patients will be included at Haukeland University Hospital and 400 at Stavanger University Hospital. The two locations use different high sensitive troponin assays (i.e. hs-cTnT and hs-cTnI (Abbott Diagnostics) for routine diagnostic of coronary syndrome. 1900 patients will be sampled and hs-cTnT or hs-cTnI (as applicable) will be measured at admission, after one (2/3 of the cohort), three hours and after 8-12 hours. Clinicians will be blinded to the results of the hs-cTn assay that is not used as routine assay locally. Final diagnosis will be made by two independent cardiologists based on all available clinical information and results of the routine tests. The ability to diagnose or exclude MI ACS, and MACE at different sampling points in different patient populations will be compared for different biomarkers. 1500 patients will have a sample 1 hour after admission. The clinicians will be blinded to the results of this sample (both hs-cTn assays). The ability of the one-hour sample to diagnose or exclude myocardial infraction (MI), ACS and MACE will be compared between biomarkers. All patients will be invited to take a follow-up sample 3 months after discharge. The patients will further be followed for 1-5 years through national registers and the prognostic value of hs-cTn concentrations and dynamics as well as other biomarkers, will be measured.

Interventions

None listed

Sponsors

Helse Stavanger HF
CollaboratorOTHER_GOV
The Royal Norwegian Ministry of Health
CollaboratorOTHER
Haukeland University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted to the Emergency Department with a clinical suspicion of acute coronary syndrome i.e. chest pain or pain radiating down the arms, the back, into the jaw, throat or into the lower teeth. Chest pain must not be the most dominant symptom but may or may not be combined with e.g. dyspnea, nausea, anxiousness or palpitations. * Age \>= 18 years

Exclusion criteria

* ST elevation MI * Age \< 18 years * Patients not able to give informed consent * Patients suffering from terminal illness (life expectance \< 1 month) * Patients already included in the study * Patients who have been stabilized at local hospitals and are referred for second opinion e.g. coronary angiography

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with chest pain that are diagnosed with acute coronary syndrome based on troponin concentrations1-3 hoursStratified according to gender, age and co-morbidities

Other

MeasureTime frameDescription
Number of patients with chest pain that are diagnosed with NSTEMI based on troponin concentration1-3 hoursStratified according to gender, age and co-morbidities
Total mortality5 yearsPatients will be followed for 1-5 years through national registers
The incidence of major cardiovascular events (MACE) defined as (composite endpoint including MI, UAP, stable angina (requiring hospitalization), revascularization, stroke, heart failure and cardiac arrhythmias)5 yearsPatients will be followed for 1-5 years through national registers
Cardiovascular mortality5 yearsPatients will be followed for 1-5 years through national registers
The incidence of major coronary events defined as (composite endpoint including MI, UAP, stable angina (requiring hospitalization), revascularization)5 yearsPatients will be followed for 1-5 years through national registers

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026